Our preclinical compound profiling capabilities cover the entire ADME spectrum to guide your project towards viable clinical drug candidates. With decades of pharma expertise, our NUVISAN scientists assist you from assay design selection to interpretation of results and implementation of screening strategies to overcome ADME liabilities and DDI risks.
We have introduced many new solutions in 2023, including Xrays2Go and Assays2Go that support clients efficiently with comprehensive data sets. To further support the biopharma ecosystem and foster scientific innovation, we launched an open platform that links innovators with investors. We look forward to continuing to grow, expand, and support each stakeholder in the biopharma industry.
As a science CRO with over ten years of experience managing multicenter and multicountry studies in Europe, NUVISAN can work with you to develop customised study designs, tailor-made solutions, and scientific consultation to support your phase II and III clinical trials.
Our microbiological chemistry team has over six decades of experience in biotransformations within the pharmaceutical and agriculture sectors. By utilizing nature's rich toolbox, we produce drug metabolites, conduct preparative biotransformations, and efficiently scale up proteins and plasmids.
NUVISAN`s scientific team has extensive knowledge in the development of chemical processes up to GMP manufacturing for pre-clinical and clinical studies. We support our clients at all points of the chemical development of their API, from early project de-risking to late-stage route scouting.
To identify drug targets, optimize drug design, and accelerate the drug discovery process, NUVISAN offers a wide array of digital life science tools including bioinformatics, molecular modeling, quantitative structure activity relationships, machine learning, as well as a 3 million compound library.
Whether you are a venture capital firm looking to invest in a new drug or therapy, or a biotech company seeking funding for your research, NUVISAN can provide the data and insights you need to derisk and advance your project further. With NUVISAN, you can access the latest research and technology to identify the most promising investment opportunities and advance the development of new drugs and therapies.
At NUVISAN, we are proud to offer a comprehensive range of toxicology solutions to support the drug discovery and development process. To assess the safety and efficacy of new drugs and therapies, as well as to identify potential toxicological concerns, we do perform in vitro and in vivo studies, as well as genetic toxicology, immunotoxicology, and safety pharmacology studies.
2022 has been a major milestone for NUVISAN as we achieved new certifications, expanded our equipment and services, and grew our team of dedicated employees. We are committed to continue providing valuable information and insights to our followers and clients, and we look forward to continue growing and expanding in the future.